Government-Owned Inventions; Availability for Licensing, 27541-27542 [E8-10682]

Download as PDF Federal Register / Vol. 73, No. 93 / Tuesday, May 13, 2008 / Notices derrick.miliner@gsa.gov, (202) 273– 3564. [FR Doc. E8–10654 Filed 5?–12–08; 8:45 am] BILLING CODE 6820–14–S DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing National Institutes of Health, Public Health Service, HHS. ACTION: Notice. AGENCY: rwilkins on PROD1PC63 with NOTICES SUMMARY: The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852–3804; telephone: 301/496–7057; fax: 301/402–0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications. Multicolored Fluorescent Cell Lines for High-Throughput Angiogenesis and Cytotoxicity Screening Description of Technology: Understanding the biological processes that underlie cellular organization and communication has become a vital element in the discovery of new therapeutics, and in evaluating the efficiency of existing therapeutic approaches. One frequently-studied example of a system in which multiple cell types function together and influence each other is angiogenesis, which is fundamentally important in tissue development, vascular disease, and cancer. The availability of highthroughput, simple assays for the study of multiple-cell biological processes, such as angiogenesis, is essential for the development of therapeutics and diagnostics for disorders governed by these complex processes. The inventors have developed a series of immortalized cell lines, selected to represent the different cell types found VerDate Aug<31>2005 16:14 May 12, 2008 Jkt 214001 in angiogenesis in vivo, that constitutively express different fluorescent proteins. Based on these cell lines, the inventors have developed several in vitro angiogenesis assays and a software application that can be used to investigate the relationships between different cells involved in angiogenesis, to develop new combinatorial approaches to boost the efficiency of existing therapeutics, and to facilitate the discovery of new potential single or combination drugs. These assays have several advantages over currentlyavailable kits, such as the capability for real-time monitoring of cellular interaction and activity, shortened and simplified protocols, and no added detection reagents to disrupt assay results. The inventors have also developed a cytotoxicity assay using these cells that would be suitable for screening libraries of potential new drugs. Applications: This technology could potentially be used to develop a highthroughput screening assay for angiogenesis or anti-angiogenesis drugs, or to screen compounds for cytotoxicity. A diagnostic test based on this technology could be used to monitor levels of angiogenic factors in the blood, to aid in personalized therapies for cancer and other angiogenesisdependent diseases. Development Status: The inventors have already demonstrated proof of concept for this technology by developing a high-throughput screen for potential angiogenic drugs, and they have also recently developed a cytotoxicity assay. They are in the process of identifying further uses for this technology, and have also developed a software application for analysis of tube formation assays. Inventors: Enrique Zudaire and Frank Cuttitta (NCI). Patent Status: U.S. Patent Application No. 12/060,752 filed 01 Apr 2008 (HHS Reference No. E–281–2007/0–US–02) Licensing Status: Available for nonexclusive licensing. Licensing Contact: Tara L. Kirby, PhD; 301–435–4426; tarak@mail.nih.gov. Collaborative Research Opportunity: The National Cancer Institute Angiogenesis Core Facility is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize multicolored fluorescent cell lines for high-throughput angiogenesis and cytotoxicity screening. Please contact John D. Hewes, PhD at 301–435–3121 or hewesj@mail.nih.gov for more information. PO 00000 Frm 00052 Fmt 4703 Sfmt 4703 27541 A Novel Growth Factor and AntiApoptotic Agent for Promoting Lung Development and Treating Lung Disease Description of Technology: This invention discloses the novel use of the uteroglobin-related protein 1 (UGRP1), also known as secretoglobin family 3A member 2 (SCGB3A2), as a cell proliferative and anti-apoptotic agent that can be used to promote lung development and treat lung disease. SCGB3A2 is a member of the uteroglobin/Clara cell secretory protein or Secretoglobin gene superfamily of secretory proteins that is normally expressed in the epithelial cells of the trachea, bronchus, and bronchioles, and is known for its anti-inflammatory activity. NIH scientists have, however, recently discovered the surprising growth factor and anti-apoptotic activities of SCGB3A2. These activities allow SCGB3A2 to be used to prevent the development of neonatal respiratory distress, promote lung development, and inhibit the lung damage that results from treatment with certain anti-cancer agents such as bleomycin. SCGB3A2 administration ex vivo and in vivo was shown to enhance cell proliferation and branching morphogenesis. SCGB3A2 was also shown to suppress or repair bleomycin induced DNA damage/fibrosis when given before, or together with bleomycin treatment in in vitro organ culture, and in an in vivo mouse model of pulmonary fibrosis. These cell proliferative and morphogenic effects of SCGB3A2 make it an attractive candidate for therapeutic use in the treatment of several lung diseases that involve tissue injury or inflammation, such as, pulmonary fibrosis, interstitial pneumonia, emphysema and cancer. SCGB3A2 therapy is also envisioned for use as a lung development agent in premature newborn infants born with underdeveloped lungs. Applications: Repair of damaged lung tissue; Lung development in premature newborn infants. Development Status: Ex vivo and in vivo mouse studies conducted. Inventors: Shioko Kimura and Reiko Kurotani (NCI). Publication: Y Chiba, R Kurotani, T Kusakabe, T Miura, BW Link, M Misawa, S Kimura. Uteroglobinrelated protein 1 expression suppresses allergic airway inflammation in mice. Am J Respir Crit Care Med. 2006 May 1;173(9):958–964. Patent Status: U.S. Provisional Application No. 60/847,747 filed 27 Sep 2006 (HHS Reference No. E–286–2006/ 0–US–01); PCT Application No. PCT/ E:\FR\FM\13MYN1.SGM 13MYN1 27542 Federal Register / Vol. 73, No. 93 / Tuesday, May 13, 2008 / Notices US2007/079771 filed 27 Sep 2007 (HHS Reference No. E–286–2006/2–PCT–01). Licensing Status: Available for exclusive or non-exclusive licensing. Licensing Contact: Jasbir (Jesse) S. Kindra, J.D., M.S.; 301–435–5170; kindraj@mail.nih.gov. Collaborative Research Opportunity: The National Cancer Institute, Laboratory of Metabolism is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize SCGB3A2 as a clinical tool to treat and/or prevent lung diseases and/or damage caused by various insults including use of the chemotherapeutic agent bleomycin. Lung diseases include pulmonary fibrosis, interstitial pneumonia, emphysema and cancer. We would like to evaluate the effect of SCGB3A2 on the development of emphysema in a smoking model mouse, and as a means to attenuate the severity of all aforementioned diseases in larger animals such as lamb, goat and monkey. We also would like to evaluate the effect of SCGB3A2 on lung maturation using pregnant larger animals. Please contact John D. Hewes, PhD at 301–435–3121 or hewesj@mail.nih.gov for more information. Dated: May 8, 2008. Steven M. Ferguson, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. E8–10682 Filed 5–12–08; 8:45 am] Agenda: The Panel will discuss the report format and recommendations for the 2007– 2008 meeting series. Place: National Cancer Institute, Office of the Director, National Institutes of Health, 6116 Executive Blvd., Suite 220, Bethesda, MD 20892 (Teleconference). Contact Person: Abby Sandler, PhD, Executive Secretary, National Cancer Institute, National Institutes of Health, 6116 Executive Blvd., Suite 220, Bethesda, MD 20892, (301) 451–9399. Any interested person may file written comments with the committee by forwarding the comments to the Contact Person listed on this notice. The comments should include the name, address, telephone number and, when applicable, the business or professional affiliation of the interested person. Information is also available on the Institute’s/Center’s home page: deainfo.nci.nih.gov/advisory/pcp/pcp.htm, where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Dated: May 7, 2008. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. E8–10679 Filed 5–12–08; 8:45 am] BILLING CODE 4140–01–P BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institutes of Health National Human Genome Research Institute; Notice of Closed Meeting rwilkins on PROD1PC63 with NOTICES National Cancer Institute; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the meeting of the President’s Cancer Panel. The meeting will be closed to the public in accordance with the provisions set forth in section 552b(c)(9)(B), Title 5 U.S.C., as amended, because the premature disclosure of information and the discussions would be likely to significantly frustrate implementation of recommendations. Name of Committee: President’s Cancer Panel. Date: May 28, 2008. Time: 11 a.m. to 1 p.m. VerDate Aug<31>2005 16:14 May 12, 2008 Jkt 214001 Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Human Genome Research Institute Special Emphasis Panel; Targeted Resequencing RFA. PO 00000 Frm 00053 Fmt 4703 Sfmt 4703 Date: June 17, 2008. Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Hotel Lombardy, 2019 Pennsylvania Avenue, NW., Washington, DC 20006. Contact Person: Ken D. Nakamura, PhD, Scientific Review Officer, Scientific Review Branch, National Human Genome Research Institute, National Institutes of Health, 5635 Fishers Lane, Suite 4076, MSC 9306, Rockville, MD 20852, 301–402–0838, nakamurk@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.172, Human Genome Research, National Institutes of Health, HHS) Dated: May 5, 2008. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. E8–10491 Filed 5–12–08; 8:45 am] BILLING CODE 4140–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Child Health and Human Development; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Child Health and Human Development Special Emphasis Panel; ACE Network Supplement. Date: June 3, 2008. Time: 12 p.m. to 2 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6100 Executive Boulevard, Room 5B01, Rockville, MD 20852 (Telephone Conference Call). Contact Person: Norman Chang, PhD, Scientific Review Administrator, Division of Scientific Review, National Institute of Child Health and Human Development, NIH, 6100 Executive Blvd., Room 5b01, Bethesda, MD 20892, (301) 496–1485, changn@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.864, Population Research; 93.865, Research for Mothers and Children; E:\FR\FM\13MYN1.SGM 13MYN1

Agencies

[Federal Register Volume 73, Number 93 (Tuesday, May 13, 2008)]
[Notices]
[Pages 27541-27542]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-10682]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally-funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by writing to the indicated 
licensing contact at the Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
MD 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A signed 
Confidential Disclosure Agreement will be required to receive copies of 
the patent applications.

Multicolored Fluorescent Cell Lines for High-Throughput Angiogenesis 
and Cytotoxicity Screening

    Description of Technology: Understanding the biological processes 
that underlie cellular organization and communication has become a 
vital element in the discovery of new therapeutics, and in evaluating 
the efficiency of existing therapeutic approaches. One frequently-
studied example of a system in which multiple cell types function 
together and influence each other is angiogenesis, which is 
fundamentally important in tissue development, vascular disease, and 
cancer. The availability of high-throughput, simple assays for the 
study of multiple-cell biological processes, such as angiogenesis, is 
essential for the development of therapeutics and diagnostics for 
disorders governed by these complex processes.
    The inventors have developed a series of immortalized cell lines, 
selected to represent the different cell types found in angiogenesis in 
vivo, that constitutively express different fluorescent proteins. Based 
on these cell lines, the inventors have developed several in vitro 
angiogenesis assays and a software application that can be used to 
investigate the relationships between different cells involved in 
angiogenesis, to develop new combinatorial approaches to boost the 
efficiency of existing therapeutics, and to facilitate the discovery of 
new potential single or combination drugs. These assays have several 
advantages over currently-available kits, such as the capability for 
real-time monitoring of cellular interaction and activity, shortened 
and simplified protocols, and no added detection reagents to disrupt 
assay results. The inventors have also developed a cytotoxicity assay 
using these cells that would be suitable for screening libraries of 
potential new drugs.
    Applications: This technology could potentially be used to develop 
a high-throughput screening assay for angiogenesis or anti-angiogenesis 
drugs, or to screen compounds for cytotoxicity. A diagnostic test based 
on this technology could be used to monitor levels of angiogenic 
factors in the blood, to aid in personalized therapies for cancer and 
other angiogenesis-dependent diseases.
    Development Status: The inventors have already demonstrated proof 
of concept for this technology by developing a high-throughput screen 
for potential angiogenic drugs, and they have also recently developed a 
cytotoxicity assay. They are in the process of identifying further uses 
for this technology, and have also developed a software application for 
analysis of tube formation assays.
    Inventors: Enrique Zudaire and Frank Cuttitta (NCI).
    Patent Status: U.S. Patent Application No. 12/060,752 filed 01 Apr 
2008 (HHS Reference No. E-281-2007/0-US-02)
    Licensing Status: Available for non-exclusive licensing.
    Licensing Contact: Tara L. Kirby, PhD; 301-435-4426; 
tarak@mail.nih.gov.
    Collaborative Research Opportunity: The National Cancer Institute 
Angiogenesis Core Facility is seeking statements of capability or 
interest from parties interested in collaborative research to further 
develop, evaluate, or commercialize multicolored fluorescent cell lines 
for high-throughput angiogenesis and cytotoxicity screening. Please 
contact John D. Hewes, PhD at 301-435-3121 or hewesj@mail.nih.gov for 
more information.

A Novel Growth Factor and Anti-Apoptotic Agent for Promoting Lung 
Development and Treating Lung Disease

    Description of Technology: This invention discloses the novel use 
of the uteroglobin-related protein 1 (UGRP1), also known as 
secretoglobin family 3A member 2 (SCGB3A2), as a cell proliferative and 
anti-apoptotic agent that can be used to promote lung development and 
treat lung disease. SCGB3A2 is a member of the uteroglobin/Clara cell 
secretory protein or Secretoglobin gene superfamily of secretory 
proteins that is normally expressed in the epithelial cells of the 
trachea, bronchus, and bronchioles, and is known for its anti-
inflammatory activity. NIH scientists have, however, recently 
discovered the surprising growth factor and anti-apoptotic activities 
of SCGB3A2. These activities allow SCGB3A2 to be used to prevent the 
development of neonatal respiratory distress, promote lung development, 
and inhibit the lung damage that results from treatment with certain 
anti-cancer agents such as bleomycin.
    SCGB3A2 administration ex vivo and in vivo was shown to enhance 
cell proliferation and branching morphogenesis. SCGB3A2 was also shown 
to suppress or repair bleomycin induced DNA damage/fibrosis when given 
before, or together with bleomycin treatment in in vitro organ culture, 
and in an in vivo mouse model of pulmonary fibrosis. These cell 
proliferative and morphogenic effects of SCGB3A2 make it an attractive 
candidate for therapeutic use in the treatment of several lung diseases 
that involve tissue injury or inflammation, such as, pulmonary 
fibrosis, interstitial pneumonia, emphysema and cancer. SCGB3A2 therapy 
is also envisioned for use as a lung development agent in premature 
newborn infants born with underdeveloped lungs.
    Applications: Repair of damaged lung tissue; Lung development in 
premature newborn infants.
    Development Status: Ex vivo and in vivo mouse studies conducted.
    Inventors: Shioko Kimura and Reiko Kurotani (NCI).
    Publication: Y Chiba, R Kurotani, T Kusakabe, T Miura, BW Link, M 
Misawa, S Kimura. Uteroglobin-related protein 1 expression suppresses 
allergic airway inflammation in mice. Am J Respir Crit Care Med. 2006 
May 1;173(9):958-964.
    Patent Status: U.S. Provisional Application No. 60/847,747 filed 27 
Sep 2006 (HHS Reference No. E-286-2006/0-US-01); PCT Application No. 
PCT/

[[Page 27542]]

US2007/079771 filed 27 Sep 2007 (HHS Reference No. E-286-2006/2-PCT-
01).
    Licensing Status: Available for exclusive or non-exclusive 
licensing.
    Licensing Contact: Jasbir (Jesse) S. Kindra, J.D., M.S.; 301-435-
5170; kindraj@mail.nih.gov.
    Collaborative Research Opportunity: The National Cancer Institute, 
Laboratory of Metabolism is seeking statements of capability or 
interest from parties interested in collaborative research to further 
develop, evaluate, or commercialize SCGB3A2 as a clinical tool to treat 
and/or prevent lung diseases and/or damage caused by various insults 
including use of the chemotherapeutic agent bleomycin. Lung diseases 
include pulmonary fibrosis, interstitial pneumonia, emphysema and 
cancer. We would like to evaluate the effect of SCGB3A2 on the 
development of emphysema in a smoking model mouse, and as a means to 
attenuate the severity of all aforementioned diseases in larger animals 
such as lamb, goat and monkey. We also would like to evaluate the 
effect of SCGB3A2 on lung maturation using pregnant larger animals. 
Please contact John D. Hewes, PhD at 301-435-3121 or 
hewesj@mail.nih.gov for more information.

    Dated: May 8, 2008.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. E8-10682 Filed 5-12-08; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.